News
-
-
PRESS RELEASE
Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs
Jaguar Health, Inc. advances towards full FDA approval of Crofelemer for treating chemotherapy-induced diarrhea in dogs, supported by positive trial results -
-
PRESS RELEASE
Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split
Jaguar Health announces approval for reverse split at April 2026 Special Meeting of Stockholders. Stock split to begin trading on split-adjusted basis on April 30, 2026. Nasdaq grants extension for compliance with $1.00 bid price rule -
-
PRESS RELEASE
Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)
Jaguar Health's crofelemer shows promise in treating pediatric intestinal failure patients with MVID and SBS. Positive results presented at ESPGHAN conference -
-
PRESS RELEASE
Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders
Jaguar Health, Inc. announces voting results of Special Meeting of Stockholders with five approved proposals for novel prescription drugs derived from plants for GI and mental health indications -
-
PRESS RELEASE
Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs
Jaguar Health plans to utilize AI platforms to enhance the development and commercialization of crofelemer for intestinal failure treatment, targeting ultrarare pediatric disorder MVID
